Northland Securities analyst Michael Grondahl maintained a Hold rating on Tilray (TLRY) today. The company’s shares closed last Tuesday at $7.78, close to its 52-week low of $2.44.
According to TipRanks.com, Grondahl is a 4-star analyst with an average return of 5.6% and a 49.1% success rate. Grondahl covers the Financial sector, focusing on stocks such as Altisource Portfolio Solutions SA, International Money Express, and WisdomTree Investments.
The word on The Street in general, suggests a Hold analyst consensus rating for Tilray with a $10.50 average price target, which is a 35.3% upside from current levels. In a report released yesterday, MKM Partners also maintained a Hold rating on the stock with a $5.00 price target.
See today’s analyst top recommended stocks >>
Based on Tilray’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $46.94 million and GAAP net loss of $220 million. In comparison, last year the company earned revenue of $15.53 million and had a GAAP net loss of $31.01 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It also supplies cannabis products to patients in a number of countries spanning five continents through its subsidiaries in Australia, Canada and Germany and it produces medical cannabis in Canada and Europe. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.